ACRV Acrivon Therapeutics, Inc.
$1.79▲ +2.87%
Healthcare
Other
Volume 132.2K
Avg Volume (10D) 168.3K
Key Metrics & Fundamentals
Market Cap
$76.71M
P/E Ratio
–
Div Yield
0.00%
52W Range
1.27 - 3.56
% vs 50 MA
-11.54%
% vs 200 MA
-1.57%
RSI-14
42.8
MACD Histogram
+0.0000
Beta (1Y vs SPY)
2.04
Free Cash Flow
-$14.95M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$18.26M
COGS
–
Operating Exp
$18.67M
Operating Income
-$18.67M
EBIT
-$18.67M
Pretax Income
-$17.96M
Net Income
-$17.96M
EPS (Diluted)
-0.43
Price & Volume History
Loading chart…
Recent News
Acrivon Advances ACR-7280, an Optimized, AP3-Enabled, Potential First-in-Class, Oral CDK11 Inhibitor Toward IND Filing in First Half of 2027
GlobeNewswire · Oct 20, 2026 8:30 AM ET
What Makes Acrivon Therapeutics, Inc. (ACRV) a New Buy Stock
Zacks · Sep 15, 2026 12:00 PM ET
Acrivon Therapeutics, Inc. (ACRV) Just Flashed Golden Cross Signal: Do You Buy?
Zacks · Sep 3, 2026 9:55 AM ET
Acrivon Therapeutics to Present at the 2026 Cantor Global Healthcare Conference
GlobeNewswire · Sep 2, 2026 8:00 AM ET
Acrivon Therapeutics Appoints Michaela Levin, Ph.D., as Chief Business Officer
GlobeNewswire · Aug 31, 2026 8:30 AM ET
Here's Why Acrivon Therapeutics, Inc. (ACRV) is a Great Momentum Stock to Buy
Zacks · Aug 24, 2026 12:00 PM ET
Acrivon Reports Second Quarter 2026 Financial Results and Highlights Upcoming 2026 Clinical Data Catalysts
GlobeNewswire · Aug 12, 2026 4:05 PM ET
Acrivon Advances ACR-2316, a Potential First-in-Class WEE1/PKMYT1 Inhibitor, into Randomized Dose Expansion in its Ongoing Phase 1/2 Study
GlobeNewswire · Aug 5, 2026 8:30 AM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See ACRV's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.